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Age is the main risk factor for a number of human diseases, including neurodegenerative disorders such as Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis, which increasing numbers of elderly individuals suffer. These pathological
conditions are characterized by progressive loss of neuron cells, compromised motor or cognitive functions, and accumulation
of abnormally aggregated proteins. Mitochondrial dysfunction is one of the main features of the aging process, particularly in
organs requiring a high-energy source such as the heart, muscles, brain, or liver. Neurons rely almost exclusively on the
mitochondria, which produce the energy required for most of the cellular processes, including synaptic plasticity and
neurotransmitter synthesis. The brain is particularly vulnerable to oxidative stress and damage, because of its high oxygen
consumption, low antioxidant defenses, and high content of polyunsaturated fats very prone to be oxidized. Thus, it is not
surprising the importance of protecting systems, including antioxidant defenses, to maintain neuronal integrity and survival.
Here, we review the role of mitochondrial oxidative stress in the aging process, with a specific focus on neurodegenerative
diseases. Understanding the molecular mechanisms involving mitochondria and oxidative stress in the aging and
neurodegeneration may help to identify new strategies for improving the health and extending lifespan.
1. Introduction
Aging is the primary risk factor for a number of human
diseases, as well as neurodegenerative disorders [1], which
increasing numbers of elderly individuals suffer. These
pathological conditions, including Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD),
amyotrophic lateral sclerosis (ALS), and spinocerebellar
ataxia (SCA), are characterized by progressive loss of neuron
cells, compromised motor or cognitive functions, and accu-
mulation of abnormally aggregated proteins [2, 3]. A growing
body of evidence highlights bioenergetic impairments as well
as alterations in the reduction-oxidation (redox) homeostasis
in the brain with the increasing of the age. The brain is com-
posed by highly differentiated cells that populate different
anatomical regions and requires about 20% of body basal
oxygen for its functions [4]. Thus, it is not surprising
that alterations in brain energy metabolisms lead to
neurodegeneration.
Cellular energy is mainly produced via oxidative phos-
phorylation taking place within mitochondria, which are cru-
cial organelles for numerous cellular processes, such as
energy metabolism, calcium homeostasis, lipid biosynthesis,
and apoptosis [5, 6]. Glucose oxidation is the most relevant
source of energy in the brain, because of its high rate of
ATP generation needed to maintain neuronal energy
demands [4]. Thus, neurons rely almost exclusively on the
mitochondria, which produce the energy required for most
of the cellular processes, including synaptic plasticity and
neurotransmitter synthesis [7]. Furthermore, given the cen-
tral role of mitochondria in energy metabolism and in the
regulation of the redox homeostasis, the study of age-
related mitochondrial disorders is becoming nowadays of
growing interest. Here, we review the role of mitochondria
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in the aging process, with a specific focus on mitochondrial
oxidative stress in neurodegenerative diseases.
2. What Is the Oxidative Stress?
Reactive oxygen species (ROS) are normally produced in the
cell of living organisms as a result of normal cellular metab-
olism and are fundamental in the maintenance of cellular
homeostasis. In physiological conditions, low to moderate
concentrations of ROS are involved in processes such as
immune response, inflammation, synaptic plasticity, learn-
ing, and memory [8]. However, the excess of ROS production
can be harmful, producing adverse oxidative modifications to
cell components including mitochondrial structures as the
first targets of ROS-induced damage [9]. Nevertheless, the
human body is equipped with a variety of antioxidants that
serve to counterbalance the effect of oxidants, including
superoxide dismutase (SOD) and the glutathione (GSH) sys-
tem [10]. When an imbalance between free radical produc-
tion and detoxification occurs, ROS production may
overwhelm antioxidant defenses, leading to the generation
of a noxious condition called oxidative stress and overall to
the impairment of the cellular functions. This phenomenon
is observed in many pathological cases involving mitochon-
drial dysfunction, as well as in aging [11] (Figure 1). The
brain is particularly vulnerable to oxidative stress and dam-
age, because of its high oxygen consumption, low antioxi-
dants defenses, and high content of polyunsaturated fats
very prone to be oxidized [12].
Biological molecules such as proteins, lipids, nucleic
acids, and carbohydrates are generally prone to oxidation,
leading to a consistent oxidative damage of the biomolecules
like change of their structures and consequently to their func-
tions. The resulting oxidative modifications of the biomole-
cules are quite stable and they could be used as markers of
oxidative and nitrosative stress. For example, the main prod-
ucts of protein oxidation are protein carbonyls and nitrated
proteins [13]. Protein carbonyls derive by the direct oxida-
tion of certain amino acids by peptide backbone scission or
by Michael addition reaction with products of lipid peroxida-
tion (e.g., HNE) or by glycoxidation reactions [14]. Detoxifi-
cation of protein carbonyls happens through enzyme such as
aldehyde dehydrogenase (ALDH) or by reduction of the car-
bonyl group to the corresponding alcohol group by carbonyl
reductase (CR) [15]. Protein nitration happens in particular
at tyrosine level (3-nitrotyrosine: 3-NT) through the action
of reactive nitrogen species (RNS) such as peroxynitrite and
nitro dioxide [16].
Another characteristic process of oxidative stress that
affects lipids and leads to the formation of the relative
markers is the lipid peroxidation. More in specific, lipid per-
oxidation derives from the damage of cellular membranes by
ROS that generates a heterogeneous group of relatively stable
end-products such as malondialdehyde (MDA), 4-hydroxy-
2-nonenal (HNE), acrolein, and isoprostanes [17]. MDA,
HNE, and acrolein are able to bind proteins and DNA lead-
ing to the alteration of conformation and function [18].
Carbohydrates are also affected by ROS. Indeed, reducing
sugars plays a pivotal role in modifying proteins through the
formation of advance glycation end-products (AGEs) in a
nonenzymatic reaction called glycation [19]. AGEs are
involved in the progress of some diseases such as diabetes
mellitus, cardiac dysfunction, and neurodegenerative dis-
eases [20].
Between all the free radicals, the hydroxy radical (OH·) is
the most toxic because of its high reactivity and limitation on
its diffusion from their site of the formation. OH· has been
found to damage biological molecules including nucleic acid
[21]. 8-Hydroxyguanosine (8-OHG) and 8-hydroxy-2′
-deoxyguanosine (8-OHdG) are the most abundant among
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Figure 1: Schematic representation of oxidative stress in health, aging, and neurodegenerative diseases. In healthy conditions, the oxidant
levels mainly produced in mitochondria are kept under control due to efficient mechanisms of defense that counterbalance the excessive
production of oxidants and keep the homeostasis. However during the aging, the oxidant levels increase, while the antioxidant efficiency
decreases generating an imbalance that leads to a noxious condition called oxidative stress and consequently to an oxidative damage of the
main biomolecules such as proteins, lipids, nucleic acids, and carbohydrates. The overall picture intensifies in neurodegenerative
conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
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the oxidized bases, and they can be used as markers of RNA
and DNA oxidation [22]. The involvement of nucleic acid
oxidation in neurodegenerative diseases might cause not only
the reduction of protein level but also translation errors
in vivo with alteration of protein structure and function [23].
In the course of the evolution, the organisms have devel-
oped several mechanisms of protection against the noxious
effects of ROS and RNS in such a way that the whole amount
of prooxidants is under control, and the negative conse-
quences are limited. The antioxidant molecules are divided
into two groups: enzymatic and nonenzymatic compounds.
The enzymatic group includes superoxide dismutase
(SOD), catalase (CAT), glutathione peroxidase (GPx), and
glutathione reductase (GR). SOD is one of the first protective
mechanisms against ROS and catalyzes the conversion of O2-
· to H2O2 and O2 [24]. The generated H2O2 is converted to
water and O2 by CAT. The nonenzymatic group involves glu-
tathione (GSH), the most abundant antioxidant in most of
the brain cells, thioredoxin (Trx), vitamins A, E, and C, and
selenium. GSH reacts with ROS generating glutathione disul-
fide (GSSG) and enters a cycle together with GPx and GR.
Vitamin E (also called α-tocopherol) is a lipophilic molecule
acting against the lipid peroxidation [25]. Vitamin C (also
called ascorbic acid) is one of the most important water-
soluble antioxidants. Selenium is a crucial cofactor for the
enzymes GPx and thioredoxin reductase (TrxR) and essential
trace elements. All together they act and balance the levels of
ROS and RNS to avoid the onset and the propagation of
harmful effect in the nearby tissues.
3. Mitochondrial Damage in Aging
Aging is a degenerative physiological process induced by the
accumulation of cellular lesions leading progressively to
organ dysfunction and death. Although our knowledge of
the aging process remains far from being complete, under-
standing the basis of human aging is one of the great biomed-
ical goals. The best known and most long-standing
hypothesis to explain aging is the “free radical theory of
aging” proposed by Harman and coworkers [26], which pos-
tulates that aging and age-associated degenerative diseases
are the result of free radical attacks on cells and tissues. This
theory was later extended by Miquel and coworkers [27] who
focused on mitochondria as the main source of ROS in aging
cells. In this relevant work, the authors explained how mito-
chondrial disorganization might be an important aspect of
the age-related changes of postmitotic cells such as neurons
and muscle cells. This view was based on electron micro-
scopic and biochemical studies on insects and mammals.
Finally, they offered a hypothesis on intrinsic mitochondrial
senescence and its possible relation to age-related changes
in other cell organelles. The theory is known nowadays as
“the mitochondrial theory of aging.” Since this early publica-
tion, experimental evidences of the implication of mitochon-
dria in aging have increased.
In addition to the energy generation through oxidative
phosphorylation, mitochondria play an essential role in cell
metabolic homeostasis, signaling, differentiation, and senes-
cence [28]. Mitochondrial dysfunction is one of the main fea-
tures of the aging process [29] (Figure 2), particularly in
organs requiring a high-energy source such as the heart,
muscles, brain, or liver. Although a large amount of data sup-
port the role of mitochondrial ROS production in aging, it
has also recently been demonstrated the involvement of the
mitochondrial permeability transition in the mechanisms of
aging [30]. Indeed, the mitochondrial membrane potential
appeared originally lower in old animals, and cellular perox-
ide levels were higher in cells from old animals with respect
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Figure 2: Rendition of the central role of mitochondrial deficiencies in aging. The ROS production in aged mitochondria is increased, the
membrane potential appeared lower, ATP synthesis is reduced, the activity of respiratory enzyme complexes is declined, and oxidized
proteins accumulate causing protein aggregation. Mitochondrial DNA (mtDNA) is also oxidized and deletions and mutations have found.
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to the young ones [31]. The age-associated decrease in mito-
chondrial membrane potential correlated with reduced ATP
synthesis in tissues of old animals [32] and also in human
fibroblasts from elderly subjects [33]. The mitochondrial per-
meability transition is due to a nonspecific pore called the
mitochondrial permeability transition pore (mPTP) occur-
ring when mitochondria become overloaded with calcium.
Indeed, it is well known that aging alters cytosolic calcium
pick-up and the sensitivity of the mPTP to calcium enhanced
under oxidative stress conditions [34].
Using isolated mitochondria, in the past few decades,
many studies revealed that the activity of respiratory enzyme
complexes in the electron chain transport gradually declines
with age in the liver, skin fibroblasts, brain, and skeletal
muscle of humans [32, 33, 35, 36] (Figure 2). Moreover,
mitochondrial morphology changed with age. Electron
microscopic studies showed that mitochondrial disorganiza-
tion accumulates with age in a variety of cells and tissues
[26]. Although mitochondria are very dynamic organelles
and can remodel their structure through fusion and fission
[37], abnormalities in the process have been related to senes-
cence in mammalian cells [38].
Age-associated oxidative damage to mtDNA was shown
to correlate with mitochondrial GSH oxidation in the liver,
kidney, and brain of rats and mice [39]. mtDNA deletions
were also found to correlate with the level of oxidized guano-
sines in mtDNA [40]. Furthermore, mtDNA increasingly
accumulated mutations with age in a variety of human tis-
sues, which include point mutations [41], large-scale dele-
tions [42], and also tandem duplications [43] (Figure 2).
On the other hand, mitochondrial rRNAs were oxidized
and degraded under oxidative stress conditions [44].
Oxidized proteins also accumulate progressively during
aging, and an important consequence is the unfolding phe-
nomenon that causes protein aggregation [45] (Figure 2).
Many respiratory enzymes are known to be the targets of
oxidation, such as complex I and ATPase [46] (Figure 2).
Finally, lipid peroxidation is particularly important in the
inner mitochondrial membrane due to the high content of
cardiolipin [47]. In fact, oxidative stress was found to
decrease cardiolipin levels more than other lipids and this
decline appeared directly related to the decrease of cyto-
chrome oxidase activity [47].
Interestingly, a switch from glycolysis to respiratory
metabolism in yeast has been found to increase ROS pro-
duction, activate the antioxidant response, and increase
NADPH production, causing lifespan extension and horm-
esis response [48].
Mitochondrial dysfunction has also been related to
another aging-related process, the telomere shortening [49].
PGC-1a/b are the principal regulators of mitochondrial bio-
genesis and function and establish the connection between
telomere shortening and mitochondria malfunction [50].
When DNA is damaged, p53 levels increase and PGC1a/b
are inhibited consequently leading to mitochondrial dysfunc-
tion [49, 50]. PGC-1a was also found to decrease its activity
inducing loss of SIRT1 activity and mitochondrial dysfunc-
tion, particularly in the muscle [51]. Interestingly, the over-
expression of PGC-1a can improve aging muscle and plays
a significant role in longevity [52]. On the other hand,
DNA damage can also activate AKT and mTORC1, resulting
in PGC-1b-dependent mitochondrial biogenesis and ROS
generation [53].
4. Mitochondrial Oxidative Stress and Its
Role in Neurodegenerative Diseases
As already described above, mitochondria are key multifunc-
tional organelles that play multiple important functions in
the cell. They are essential not only in energy production
but also in thermogenesis, calcium homeostasis, generating
and maintaining key cellular metabolites, and redox signal-
ing [5]. Neurons are postmitotic highly differentiated cells
with a lifespan similar to that of the whole organism [54].
These excitable cells are more sensitive to the accumulation
of oxidative damages compared to dividing cells and are
more prone to accumulating defective mitochondria during
aging [54, 55]. Thus, it is not surprising the importance of
protecting systems, including antioxidant defenses, to main-
tain neuronal integrity and survival.
All the neurodegenerative disorders share several com-
mon features, such as the accumulation of abnormally aggre-
gated proteins and the involvement of oxidative damage and
mitochondrial dysfunction. Many of the genes associated
with PD or ALS are linked to mitochondria. In addition, all
aggregated misfolded proteins (β-amyloid, tau, and α-synu-
clein) are known to inhibit mitochondrial function and
induce oxidative stress [56]. Therefore, the identification of
common mechanisms underlying neurodegenerative dis-
eases, including mitochondrial dysfunction, will increase
our understanding of the essential requirements for neuronal
survival that can inform future neuroprotective therapies.
5. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most prevalent neurodegen-
erative disorder affecting the aged population, which is char-
acterized by progressive deterioration of behavior, cognition,
and functionality [57]. Although the pathophysiology is
extremely complex and heterogeneous, the main hallmarks
of AD are the senile plaques composed by extracellular
deposition of amyloid beta (Aβ) peptide and the presence
of intracellular tau neurofibrillary tangles (NFT) [57]. The
aberrant protein aggregation results in multifactorial neuro-
nal dysfunction affecting synaptic signaling, mitochondrial
function, neuroinflammation, and neuronal loss [58, 59].
In particular, Aβ plaques were found to deplete Ca2+ ions
storage in the endoplasmic reticulum (ER), resulting in cyto-
solic Ca2+ overload, which causes a reduction in endogenous
GSH levels and ROS accumulation [60]. ROS-induced oxi-
dative stress is one of the main important factors in the
pathogenesis of AD as ROS overproduction is thought to
play a critical role in the accumulation and deposition of
Aβ peptides in AD [61].
The relationship between mitochondria and AD pathol-
ogy is not so direct compared to other neurodegenerative
disorders, although the role of oxidative stress and mito-
chondrial dysfunction is shown in different AD models
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[62]. Thus, a reduction in complex IV activity has been dem-
onstrated in mitochondria from the hippocampus and plate-
lets of AD patients and in AD cybrid cells [63, 64].
Aggregation of Aβ peptides leads to oxidative stress, mito-
chondrial dysfunction, and energy failure prior to the
development of plaque pathology [65] and can reduce
mitochondrial respiration in neurons and astrocytes via
the inhibition of complexes I and IV, thus causing ROS
production [66]. The important role of mitochondrial
ROS has been also confirmed by the results obtained with
the antioxidant MitoQ, which can prevent cognitive
decline, Aβ peptide accumulation, microglia inflammation,
and synaptic loss in a transgenic mouse model of AD [67]
and can extend lifespan and improve health in a transgenic
Caenorhabditis elegans model of AD [68]. In addition, the
inhibition of oxidative stress as a result of a polyunsaturated
fatty acid diet improved cognition and memory in mice [69],
rats [70], and protected worms from the paralysis by extend-
ing their lifespan [71].
It has been reported that the H2O2 production from syn-
aptic mitochondria was more than fivefold higher than that
from nonsynaptic mitochondria [72]. This fact indicates that
neurons are more susceptible to oxidative damage than glial
cells. Furthermore, isolated mitochondria from neurons
incubated with Aβ peptides caused a fivefold increase in the
rate of H2O2 production [73]. Moreover, Aβ peptides
increased the aggregation of mitochondria isolated from neu-
rons and caused cytochrome C release from mitochondria,
both proapoptotic signals [73]. Studies performed in AD
patients showed reduced cytochrome oxidase activity in
platelets of AD subjects when compared to controls [74],
and this mitochondrial defect was also demonstrated in the
brain of AD patients [75]. Mitochondria from platelets of
AD patients have been found depolarized, smaller on aver-
age, and less able to buffer calcium, showing lower ATP levels
and an increase of oxidative stress, stress signaling, and apo-
ptosis, with respect to controls [7]. Subjects with mild cogni-
tive impairment also revealed mitochondrial deficiencies
[76]. Fisar et al. have recently shown that both insufficiency
in substrates entering into the oxidative phosphorylation sys-
tem and functional disturbances in the electron transport
system complex are responsible for the decrease in respira-
tion observed in intact platelets of AD patients [77]. A very
early decrease in mitochondrial complex activity has also
been found in the entorhinal cortex of AD patients, but not
in the frontal cortex [78].
Recently, it has been suggested that an imbalance in
nuclear and mitochondrial genome-encoded oxidative phos-
phorylation transcripts may drive a negative feedback loop
reducing mitochondrial translation and compromising oxi-
dative phosphorylation efficiency, leading to ROS production
[79]. Indeed, a deficiency of the mitochondrial oxidative
phosphorylation system can impact directly on mitochon-
drial function and result in several disease phenotypes [80].
It has recently been shown that cells from late-onset AD
patients exhibited an impaired mitochondrial metabolic
potential and an abnormal redox potential, associated with
reduced nicotinamide adenine dinucleotide metabolism and
altered citric acid cycle activity [81]. Moreover, AD
fibroblasts presented a significant reduction in mitochondrial
length, changes in the expression of proteins that control
mitochondrial fusion, and dysfunction of mitochondrial bio-
energetics [82]. Martín-Maestro et al. also showed that mul-
tiple genes that control mitochondrial homeostasis, including
fission and fusion, are downregulated in Alzheimer’s
patients. These defects lead to strong accumulation of aged
mitochondria in AD fibroblasts [83]. Accordingly, the analy-
sis from AD patients of genes involved in autophagy and
mitophagy demonstrated a downregulation, indicating that
the recycling mechanism of these aged mitochondria might
be impaired [83].
AD pathogenesis has also been linked to voltage-
dependent anion channel 1 (VDAC1) [84], which is
expressed in the mitochondrial outer membrane and regu-
lates the main metabolic and energetic functions of the
cell, including Ca2+ homeostasis, oxidative stress, and
mitochondrion-mediated apoptosis. Indeed, VDAC1 levels
were found to increase in the AD brains and its inhibition
has been proposed as the target of a novel strategy for
diminishing cell death [84].
Mitochondria are highly abundant in synapsis cause of
their on-site energy provision and calcium modulation [85].
Via TOM import machinery [86] and/or by local production
by γ-secretase [87], Aβ peptides accumulate inside the syn-
aptic mitochondria [88]. Then, it probably interacts with
the mitochondrial heme group [73] and/or with mitochon-
drial matrix proteins such as amyloid-binding alcohol dehy-
drogenase (ABAD) [188] and blocks the electronic transport
thereby compromising ATP production [89] and synaptic
function [64]. A recent study performed in isolated mamma-
lian mitochondria showed that Aβ peptides impaired mito-
chondrial import of nuclear-encoded precursor proteins
due to a coaggregation process [90].
It has been showed from different laboratories that oxida-
tive and nitrosative stress markers were substantially
increased in AD, encouraging the idea about the crucial role
of these two pathways in the progression of the disease. In
several postmortem cortex areas not only from sporadic
and familiar AD patients but also from patients affected by
mild cognitive impairment (MCI), the levels of protein car-
bonyls were substantially increased compared to age-
matched control subjects [91, 92]. In addition, the levels of
carbonyl reductase (CR) were also found to increase in the
AD brains, suggesting that the brain tries to counteract pro-
tein oxidation [15]. About markers of nitrosative stress in
AD, proteomic approaches have identified a large number
of proteins which are nitrated in the MCI and AD brains
[93, 94]. These proteins are involved in several cellular func-
tions such as energy metabolism, structural maintenance, pH
regulation, and antioxidant.
Lipid peroxidation seems to play a particular role not
only in aging but also in the pathogenesis of AD [95] and
its products could be used as markers for AD identification
since early stages (MCI). Indeed, in CSF and the brains from
AD and MCI subjects, it has been found elevated levels of
lipid peroxidation products such as HNE, malondialdehyde
(MDA), acrolein, F(2)-isoprostane, F(4)-isoprostane, and neu-
roprostane [96, 97], have been found elevated, while MDA
5Oxidative Medicine and Cellular Longevity
levels was also found high in plasma and serum from AD
patients [98] and colocalized with neurofibrillary tangles
and senile plaques [99]. The decrease of the detoxification
system efficiency in MCI and AD caused the accumulation
of HNE protein adducts in neuronal cells [100]. Also in the
blood, a significant increase of HNE levels has been found
in AD patients compared to healthy subjects [101]. Acrolein
has been reported to react with DNA bases leading to the for-
mation of acrolein-deoxyguanosine in the AD brain [102].
Several papers published in the early nineties suggested
an important role of glycation in the formation of neurofi-
brillary tangles and senile plaques [103, 104]. Like many
other markers of oxidative stress, AGEs were also found to
increase in CSF of AD patients, as well as their receptor levels
in microglia cells of the AD brains [104]. While the picture
in the brain is clear, the results about AGEs and soluble
RAGE levels obtained in the blood from AD patients are
controversial [105].
A considerable amount of evidences supports the early
involvement of nucleic acids and oxidation in the cascade
of neurodegeneration. DNA and RNA damage is a feature
of the AD brain as well as of peripheral tissue [106]. mtDNA
of cortical neurons in AD patients was found deleted with
respect to age-matched controls [107]. Later, sporadic muta-
tions in the mtDNA control regions in AD patients were also
identified [108]. Interestingly, 8-OHdG levels in the mtDNA
of the cerebral cortex and cerebellum from AD patients were
threefold higher than in age-matched controls [109]. RNA
oxidation was observed in the postmortem brains of early
and latest stages of AD [110], a presymptomatic case with
familial AD mutation [111], and Down syndrome with AD
pathology [112], suggesting that mRNA is highly sensitive
to oxidative damage. Fivefold increase in oxidized RNA was
also observed in CSF of AD cases [113]. All this data suggests
that nucleic acid oxidation may be considered an early event
in the progression of AD.
The antioxidant levels in AD were found to change not
only in the brain but also in peripheral tissues. Most of the
studies have found an overall decrease in antioxidant amount
and activity in the blood of AD patients since the early
phases, suggesting that the physiological equilibrium
between ROS/RNS production and antioxidant is altered
and consequently the amount of antioxidant available is
strongly compromised. In particular, SOD levels, but not
the activity [114], were found to be elevated in the hippocam-
pus and amygdala of AD patients [115], while a decrease in
SOD, GPx, and CAT levels was found in the frontal and
temporal cortex [116]. Nevertheless, CAT activity was
found to increase in AD erythrocytes [117], suggesting an
independence of the redox status between the periphery
and the brain.
GSH was also found to decrease in theMCI and AD brain
and erythrocytes [114, 118]. Another recent study showed
higher GSH levels in the anterior and posterior cingulated
from MCI patients [119]. In addition to GSH, the enzymes
involved in its metabolism were also analyzed. In particular,
glutathione-S-transferase (GST), a sensitive target of oxida-
tive and nitrosative stress, was found to be carbonylated in
C. elegans expressing Aβ42 [120] and in canine model of
aging [121]. GST was also found to be nitrated in inferior
parietal lobe (IPL) from MCI patients [122] and significantly
elevated in the AD hippocampus, causing a decrease of its
activity [118]. Since GSTs catalyze the conjugation of HNE
to glutathione (GSH), the decline of its activity consequently
leads to the compromise of detoxification process of HNE
[123] and an accumulation of HNE-modified proteins. All
these studies suggest that an alteration of GSH metabolism
at the early stages of the disease could be an early marker
for the detection of AD.
Another family of antioxidants particularly affected by
oxidative and nitrosative stress is peroxiredoxins (Prxs),
which reduces H2O2 [124] and presents a redox-regulated
chaperone activity [125]. Prx2 oxidation was found Aβ42
dependent in SAMP8 mice [126]. However, Prx2 expression
was found to increase in the AD brains [127] and Prx6 is oxi-
datively modified in the MCI brains [122], suggesting the
presence of a compensatory mechanism.
Vitamins E and C were also found to decrease in
plasma fromMCI and mild AD and in CSF from AD patients
[128–130]. In line with these results, another study showed a
positive correlation between plasma vitamin E levels and the
risk to develop AD in an advanced age [131].
Selenium levels were also affected in AD plasma with an
association to the cognitive decline [132]. Nevertheless, the
plasma levels of selenium seem to be independent from those
of the brain [133]. The levels of seleno-containing enzyme
Trx1 were also found to increase in the AD brains [134], in
particular in glial cells, but not in neurons [135]. On the
contrary, the long cleavage product of Trx1, Trx80, was
drastically reduced in the brains and CSF from AD and
MCI patients and it could be used to distinguish the stable
MCI from the MCI that evolve later to AD [136].
6. Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neu-
rodegenerative disorder, after AD, which is characterized
by the progressive degeneration of the dopaminergic neu-
rons located in the substantia nigra (SN) pars compacta
[137]. The main neuropathological hallmark of PD is the
presence of intracellular inclusions known as Lewy bodies
(LBs) and neurites (LNs) [138], predominantly composed
by misfolded and aggregated forms of the presynaptic pro-
tein α-synuclein [139].
The implication of mitochondrial dysfunction in the
pathology of PD has been shown for a long time [140, 141].
The aging-related mitochondrial decline and the increasing
mtDNA damage/mutations are also been associated with
the increased risk for PD [142]. Indeed, it has been reported
that mtDNA can impair the capacity of the organelle quality
control mechanisms and thereby amplify the initial insult
through a progressively increase of metabolic dysfunction
and oxidative stress [143]. In particular, in some models
of PD, it has been shown that environmental xenobiotics
were extremely toxic and caused mitochondrial dysfunc-
tion in dopaminergic neurons leading to parkinsonian
phenotypes [144].
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Furthermore, the protein α-synuclein associated with PD
pathogenesis is known to target the mitochondria and to
decrease their function [140–142, 145, 146]. Notably, a
decline of complex I activity and elevated intracellular ROS
have been reported in the SN of the postmortem brain of
PD patients [140, 147]. The implication of the mitochondria
in PD is also supported by the presence of PD-related genes
such as PINK1, PARK2 (Parkin), DJ-1, and LRRK2 which
regulate mitochondrial and ROS homeostasis [148–151].
PINK1 deficiency results in impaired respiration with inhibi-
tion of complex I, and mutations in PINK1 gene cause a
recessive form of PD [152, 153]. Abnormal ROS production
in the mitochondria of PINK1 knockout neurons has been
found to inhibit the mitochondrial Na2+/Ca2+ exchanger or
glucose transporter and to be prevented by antioxidants
[152, 154]. Mitochondrial ROS play an important role not
only in the pathology of PINK1 (mutation or deficiency)
but also in the physiology of PINK1/Parkin-related mito-
phagy, by the induction of mitochondrial recruitment of Par-
kin [155]. In addition, it has recently been reported that
mitochondrial ROS production in familial and sporadic
forms of PD caused DNA damage and activated the PARP
enzyme-associated DNA repair mechanism [156].
Although monomeric α-synuclein is a physiological reg-
ulator of synaptic transduction and mitochondrial bioener-
getics [157], the oligomeric species appeared toxic for cells
[62, 158], inhibited mitochondrial complex I [159], and
induced mitochondrial depolarization [160]. In addition,
oligomeric α-synuclein caused ROS production [158] inde-
pendently of the known enzymatic pathways that affected
mitochondrial function and induced lipid peroxidation
[161]. The role of α-synuclein in mitophagy, mitochondrial
fission/fusion, and protein trafficking to this organelle has
also been shown [162]. Neurodegenerative impairments were
also found in α-synuclein transgenic mice through the activa-
tion of mPTP [163]. The opening of mPTP appeared to be
induced by oligomeric α-synuclein with respect to the mono-
meric protein, due to their ability to induce calcium signal in
a structure-specific manner [164] and to produce ROS in the
presence of free metal ions [165].
In addition to the mitochondrial dysfunction and ROS
production, PD is characterized by an overall increase of
end-product markers of oxidative and nitrosative stress that
reflects an extensive damage on the biomolecules. This
strongly suggests that these three processes are intercon-
nected and create a cascade of events promoting a neurode-
generative condition like PD. The SN from the postmortem
brains showed increased protein carbonyl levels at high
molecular weight compared to the control brains or other
brain regions [165]. The levels of protein nitration were also
found to increase in the PD brains [166]. A recent study
showed increased α-synuclein nitration levels in the brain
from individuals with synucleinopathy, suggesting a direct
link between nitrosative damage and the progression of neu-
rodegenerative synucleinopathies [167]. Interestingly, an
in vitro study showed the nitration of mitochondrial complex
I that might trigger overtime a cascade of deleterious events
enhancing the overall oxidative damage in PD [168]. The
postmortem brains of PD patients showed increased levels
of lipid peroxidation markers and oxidized proteins [169].
In particular, HNE adducts were identified in dopaminergic
cells of SN, CSF, and plasma from PD patients [170, 171]
and significant differences were found in plasma of PD sub-
jects treated with L-dopa therapy [171]. Moreover, MDA
levels were found to be high and attached to α-synuclein in
the SN and frontal cortex of PD cases [172] supporting the
idea that lipid peroxidation might precede and contribute
to α-synuclein aggregation. In PD plasma, MDA levels were
also found to be increased and inversely related to the age
of patients [173]. Glycation also showed a strong immunore-
activity in the SN and locus coeruleus of PD patients [174],
suggesting its involvement in the chemical cross-linking,
proteolytic resistance, and aggregation process. Overall, the
levels of glycated proteins were significantly higher in the
cerebral cortex of PD patients compared to age-matched
controls [175]. Since in PD the catabolic pathway activity of
the most glycation agents is lower [176], the AGE concentra-
tion rises up leading to the death of dopaminergic neurons.
About DNA and RNA oxidation, the levels of 8-OHdG and
8-OHG were also found to be increased in different brain
regions, including SN, in serum and CFS [177, 178].
The antioxidant status of PD was found significantly
modified compared to age-matched healthy subjects, as well
as in AD. In particular, SOD levels, but not the activity, were
found to increase in the SN and basal ganglia from PD
patients [179]. In contrast, the levels of other antioxidant
enzymes such as CAT, GPx, and GR did not change in PD
compared to the age-matched healthy subject [179]. GSH
levels were found to decrease only in the SN [180]. Interest-
ingly, blood GSH/GSSG ratio was found to increase when
the patients stopped to take PD medication such as dopa-
mine receptor agonist suggesting how the medication could
strongly influence the peripheral redox status [181].
Anyway, studies in the animal models of PD showed dif-
ferent outcomes compared to the human sample analysis
with a degree of controversy [182, 183] probably due to the
temporal length of the experimental observation time.
7. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by progressive loss of motor neurons
in the anterior horn of the spinal cord, leading to muscle
weakness, wasting, and spasticity [184]. ALS is classified as
either familial or sporadic depending on whether there is a
clearly defined, inherited genetic element. The onset of spo-
radic (sALS) is unknown, and thus, the identification of
causal genes and environmental factors remains elusive.
Mutations in the first ALS gene superoxide dismutase 1
(SOD1) were found in 1993 to segregate in several fALS ped-
igrees [185] and subsequently in a small number of unrelated
sALS cases [186]. Fifteen years later, TAR DNA binding pro-
tein 43 (TDP-43) is found to be an important constituent of
protein aggregates frequently observed in postmortem mate-
rial of ALS patients [187]. Although it is not yet clear how
such aggregates trigger neurodegeneration in ALS, mutations
in the TDP-43 gene were reported in 3% of fALS and 1-5% of
patients with sALS, suggesting that TDP-43 aggregates have a
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central role in triggering ALS [188, 189]. The number of ALS
genes increases and it appears that the mutant proteins
encoded are involved in a variety of critical processes, includ-
ing mitochondria function.
The link of mitochondria to ALS has been defined by the
mutations in SOD1 gene since they were found in 20% of the
fALS [190]. SOD1 is an ubiquitous enzyme with several func-
tions, including scavenger of excessive superoxide radical
(O2
–·) into oxygen, modulation of cellular respiration, energy
metabolism, and posttranslational modification [191]. Sev-
eral SOD1 mutations were shown to affect the folding of
the protein, and it is believed that the ensuing toxic gain of
function might be caused by the accumulation of misfolded
proteins inside the intermembrane space of mitochondria
[192] with generation of free radicals that eventually lead to
cell injury and death [193, 194]. Even if this may not be the
main triggering mechanism, it is nonetheless recognized that
mitochondrial dysfunction is central to SOD1 pathogenesis
[195]. Although SOD dysfunction leads to a loss of antioxi-
dant capability, evidences have shown that the silencing of
SOD1 in mice does not lead to neurodegenerative conditions
[196]. In contrast, it has recently been reported that mutant
SOD1 can disturb the amino acid biosynthesis of cells in a
yeast model and mediate cellular destruction, accounting
for the neural degeneration in ALS [197]. In addition, the
reduction of the mitochondrial ROS in neurons of a double
UCP-SOD1 transgenic mouse model did not recover mito-
chondrial function and accelerated the progression of the dis-
ease [198]. The activity of SOD was also found to reduce in
red blood cells from ALS patients [199], while SOD1 activity
in the CSF showed conflicting results [200, 201].
Mitochondrial oxidative damage has also been demon-
strated in patients affected by sALS [202] and in a transgenic
mouse model expressing a fALS-linked mutant Cu/Zn SOD1
[203]. The spinal cord and motor cortex showed increased
levels of protein carbonyls, nitrosative stress, and NOS
[204, 205] suggesting selectivity about protein oxidation
and nitration in ALS. Mutations of other genes associated
with ALS, such as TDP-43, FUS/TLS, and p62, were also
found to increase mitochondrial ROS and oxidative stress
[206, 207]. In addition, exogenous-added TDP-43 aggregates
were found to accumulate in the cytosol of neuronal cells
causing intracellular ROS production [208].
Modifications in HNE-bound proteins have been
detected in ventral horn motor neurons [209], and high free
HNE levels were found high in CSF and serum of ALS
patients [210, 211] suggesting a diffusion of HNE from the
brain to the periphery. Proteomic analysis on the spinal cord
of an ALS mouse model and in CSF [212] revealed an
increase in lipid peroxidation, which was also found to
increase the levels of MDA-protein adducts in the lumbar
spinal and cervical cord before the onset of clinical motor
signs in a murine model of ALS [213]. Despite acrolein-
protein adducts were not detectable in the spinal cord of
ALS patients, free MDA detection has been also confirmed
in ALS subjects [205].
Glycation was first detected in the spinal cord and brain
samples of both sALS and fALS [214, 215] as well as in
SOD1 transgenic mice. Surprisingly, the levels of soluble
RAGE were found lower in serum of ALS patients with
respect to control subjects [216]. From a mechanistical point
of view, in vitro glycation affected negatively the structure
and the activity of SOD1 [217]. The roles of mRNA and
DNA oxidation were showed for the first time in a mouse
model of ALS, suggesting the presence of an early event
before the degeneration of the motor neurons and appear-
ance of all the symptoms. ALS patients presented an increase
of nuclear 8-OHdG in the motor cortex and 10-fold higher in
the spinal cord tissue [205], as well as in plasma, urine, and
CSF, compared to healthy people [218].
In addition to SOD1, other antioxidants showed changes
in level and activity in peripheral tissues or CFS. Anyway, the
modification of GSH, GPx, and GR activities appears fluctu-
ating in the analyzed samples, suggesting a grade of variabil-
ity [219], together with the variability of the pathogenic
mechanisms that both lead to a fluctuation in the antioxidant
profiles of ALS patients [220]. In some studies, the levels and
the activities of these enzymes were found to decrease in
erythrocytes [221] and in the motor cortex [222] from ALS
patients. However, in another study, the GSSG/GSH ratio
was found to decrease [223], and the GPx level and the GR
activity were enhanced in erythrocytes, serum, and CSF
[201, 224, 225]. Moreover, other studies showed that GR
activity in red blood cells from ALS patients did not change,
whereas CAT levels and activity were diminished [201, 224].
In addition, plasma levels of nonenzymatic antioxidants were
inconsistent, with some studies showing elevated levels [226]
and other with no change [227] proving again the grade of
variability of the disease.
8. Mitochondrial Dynamics
and Neurodegeneration
Mitochondria are organelles with high mobility inside the
cells. They can change size, morphology, and position and
can also suffer fission and fusion. Fission is the process to
obtain two or more daughter mitochondria from the division
of a single. Fusion is the opposite: the union of two or more
mitochondria to form a unique structure [228] (Figure 3).
Fission and fusion are normal processes that occur continu-
ously in many cell types. Fission is facilitated by Drp1, a pro-
tein with GTPase activity which in the mitochondrial outer
membrane forms chains promoting the mitochondrial divi-
sion. The chain is stabilized by MiD49 and MiD51 proteins
that previously form a complex with Mff and Fis1
(Figure 3). Fusion is mediated by OPA-1 which controls the
mitochondrial inner membrane fusion and by Mfn1 and
Mfn2 which control the mitochondrial outer membrane
fusion [229] (Figure 3).
Mitochondrial dynamics were found to be impaired in
neurodegeneration. In particular, the AD brains showed
abnormal expression of mitochondrial fusion and fission
proteins [230], but the results are controversial. Indeed,
Wang et al. reported that levels of Opa1, Drp1, Mfn1, and
Mfn2 are significantly decreased, whereas the levels of Fis1
increased in the hippocampus of AD patients [231]. How-
ever, another study found increased levels of Fis1 and Drp1
and decreased levels of Mfn1, Mfn2, and Opa1 in the AD
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frontal cortex [232]. Moreover, the knock-in mouse Drp1+/-
crossed with a mouse model of AD exhibited improved mito-
chondrial function [233].
Mitochondrial fission and fusion were also found to be
altered in PD patients, with increased levels of p-Drp1 in
white cells [234]. Moreover, α-synuclein induced the
inhibition of mitochondrial fusion [235] by interacting
with outer membrane lipids. Experiments performed in
Drosophila showed that Parkin and PINK1 regulate
mitochondrial dynamics in a Drp1-depending manner
[236]. Both proteins are implicated in mitophagy [237]
and also in mitochondrial distribution in axons [238].
DJ-1, another important PD-related protein, also regu-
lates mitochondrial fission as consequence of a race in
ROS production and its effects can be reversed by over-
expression of Parkin and PINK1 [239]. Moreover, LRRK2
was also found to change Drp1 leading to mitochondrial
fragmentation [240].
Lastly, mitochondrial dynamics were also altered in ALS.
Indeed, an increase in mitochondrial fission is due to exces-
sive Drp1 levels in the ALS models [241]. Moreover, changes
in the levels of Fis1, Mfn1, OPA1, and Drp1 preceded moto-
neuron loss and symptom onset in SOD1 mutant [242].
Mitochondrial fragmentation was also found to increase
both in mutant TDP-43 and FUS, and the expression of
mitochondrial fission and fusion regulators appeared modi-
fied [243, 244]. Moreover, the inactivation of Drp1 or
Mfn2 prevented the deficits in mitochondrial trafficking
in motoneurons of mutant SOD1 or TDP-43 [243, 245].
Taking into account that mitochondrial fission and fusion
proteins regulate the assembly of respiratory complexes, the
direct involvementofmitochondrialfissionandfusiondynam-
ics in mitochondrial bioenergetics could be central [246].
Therefore, it is reasonable to point out that altered mitochon-
drial fission and fusion is probably a mechanism leading
to mitochondrial dysfunction in neurodegeneration.
9. Conclusion
Neurodegenerative diseases are becoming increasingly prev-
alent in our aged populations, thus representing a primary
health problem especially for this age group [4, 247]. Tre-
mendous efforts have been already made to identify neuro-
pathological, biochemical, and genetic biomarkers of the
diseases for a diagnosis at earlier stages.
In the past thirty years, an extensive research has been
performed to understand the role of mitochondria and oxi-
dative stress not only in physiological aging, but also in neu-
rodegenerative diseases. The whole outcome clearly affirms
that both processes get impaired during aging and are estab-
lished features significantly involved in the progress, if not
the onset, of neurodegenerative disorders. In this moment,
it is still not clear if mitochondrial dysfunction and oxidative
stress could be used as markers for an early detection of aging
dysfunctions or be a valid therapeutic target. However, a bet-
ter knowledge of the mechanism involving mitochondria and
oxidative stress in the aging process and neurodegeneration
may elicit new strategies for improving the quality of life of
Fis1
Drp1
MiD49
MiD51
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Mff
Mfn1
Mfn2
Fusion
Fiss
ion
Figure 3: Schematic representation of mitochondrial dynamics. Drp1 in mitochondrial outer membrane forms chains promoting fission. The
chain is stabilized by MiD49-Mff/Fis1 and MiD51-Mff/Fis1 complexes. Fusion is mediated by OPA-1 in the mitochondrial inner membrane
and by Mfn1 and Mfn2 in the mitochondrial outer membrane. Drp1: dynamin-related protein-1; Fis1: mitochondrial fission protein 1; Mff:
mitochondrial fission factor; MiD49: mitochondrial dynamics proteins of 49 kDa; MiD51: mitochondrial dynamic proteins of 51 kDa; OPA-1:
optic atrophy 1; Mfn1: mitofusins 1; Mfn2: mitofusins 2.
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the elderly and it would have a positive impact on the entire
modern society.
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